Research ExplorerPublicationsThe HER2 phenotype of circulating tumor cells in HER2-positi...

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer

Standard

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer : A translational research project of a prospective randomized phase III trial. / Jaeger, B A S; Neugebauer, J; Andergassen, U; Melcher, C; Schochter, F; Mouarrawy, D; Ziemendorff, G; Clemens, M; V Abel, E; Heinrich, G; Schueller, K; Schneeweiss, A; Fasching, P; Beckmann, M W; Scholz, Ch; Friedl, T W P; Friese, K; Pantel, K; Fehm, T; Janni, W; Rack, B.

In: PLOS ONE, Vol. 12, No. 6, 2017, p. e0173593.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Jaeger, BAS, Neugebauer, J, Andergassen, U, Melcher, C, Schochter, F, Mouarrawy, D, Ziemendorff, G, Clemens, M, V Abel, E, Heinrich, G, Schueller, K, Schneeweiss, A, Fasching, P, Beckmann, MW, Scholz, C, Friedl, TWP, Friese, K, Pantel, K, Fehm, T, Janni, W & Rack, B 2017, 'The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial', PLOS ONE, vol. 12, no. 6, pp. e0173593. https://doi.org/10.1371/journal.pone.0173593

APA

Jaeger, B. A. S., Neugebauer, J., Andergassen, U., Melcher, C., Schochter, F., Mouarrawy, D., Ziemendorff, G., Clemens, M., V Abel, E., Heinrich, G., Schueller, K., Schneeweiss, A., Fasching, P., Beckmann, M. W., Scholz, C., Friedl, T. W. P., Friese, K., Pantel, K., Fehm, T., ... Rack, B. (2017). The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLOS ONE, 12(6), e0173593. https://doi.org/10.1371/journal.pone.0173593

Vancouver

Jaeger BAS, Neugebauer J, Andergassen U, Melcher C, Schochter F, Mouarrawy D et al. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial. PLOS ONE. 2017;12(6):e0173593. https://doi.org/10.1371/journal.pone.0173593

Bibtex

@article{73fb0e3121ed4a468d68922affbb63eb,
title = "The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial",
abstract = "BACKGROUND: HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the primary tumor and circulating tumor cells (CTCs). This study analyzed the HER2 status of CTCs in patients with HER2-positive primary breast cancer at the time of diagnosis. Aim of the study was to assess potential discordance of HER2 status between primary tumor and CTCs, as this may have important implications for the use of HER2-targeted therapy.METHODS: The number and HER2 status of CTCs out of 30ml peripheral blood were assessed in 642 patients using the CellSearch System (Janssen Diagnostics, USA). The cutoff for CTC positivity was the presence of at least 1 CTC, and the cutoff for HER2 positivity of CTCs was the presence of at least 1 CTC with a strong HER2 staining.RESULTS: 258 (40.2%) of the 642 patients were positive for CTCs (median 2; range 1-1,689). 149 (57.8%) of these 258 patients had at least 1 CTC with strong HER2 staining. The presence of HER2-positive CTCs was not associated with tumor size (p = 0.335), histopathological grading (p = 0.976), hormone receptor status (ER: p = 0.626, PR: p = 0.263) or axillary lymph node involvement (p = 0.430). Overall, 83 (32.2%) of the CTC-positive patients exclusively had CTCs with strong HER2 staining, whereas 31 (12.0%) had only CTCs with negative HER2 staining. Within-sample variation in the HER2 status of CTCs was found in 86 (57.8%) of the 149 patients with more than 1 CTC.CONCLUSION: This study demonstrated that discordance between the HER2 expression of CTCs and that of the primary tumor frequently occurs in early breast cancer. Future follow-up evaluation will assess whether this discrepancy may contribute to trastuzumab resistance.",
keywords = "Adult, Aged, Biomarkers, Tumor, Breast Neoplasms, Female, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasm Staging, Neoplastic Cells, Circulating, Receptor, ErbB-2, Translational Medical Research, Trastuzumab, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial",
author = "Jaeger, {B A S} and J Neugebauer and U Andergassen and C Melcher and F Schochter and D Mouarrawy and G Ziemendorff and M Clemens and {V Abel}, E and G Heinrich and K Schueller and A Schneeweiss and P Fasching and Beckmann, {M W} and Ch Scholz and Friedl, {T W P} and K Friese and K Pantel and T Fehm and W Janni and B Rack",
year = "2017",
doi = "10.1371/journal.pone.0173593",
language = "English",
volume = "12",
pages = "e0173593",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

RIS

TY - JOUR

T1 - The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer

T2 - A translational research project of a prospective randomized phase III trial

AU - Jaeger, B A S

AU - Neugebauer, J

AU - Andergassen, U

AU - Melcher, C

AU - Schochter, F

AU - Mouarrawy, D

AU - Ziemendorff, G

AU - Clemens, M

AU - V Abel, E

AU - Heinrich, G

AU - Schueller, K

AU - Schneeweiss, A

AU - Fasching, P

AU - Beckmann, M W

AU - Scholz, Ch

AU - Friedl, T W P

AU - Friese, K

AU - Pantel, K

AU - Fehm, T

AU - Janni, W

AU - Rack, B

PY - 2017

Y1 - 2017

N2 - BACKGROUND: HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the primary tumor and circulating tumor cells (CTCs). This study analyzed the HER2 status of CTCs in patients with HER2-positive primary breast cancer at the time of diagnosis. Aim of the study was to assess potential discordance of HER2 status between primary tumor and CTCs, as this may have important implications for the use of HER2-targeted therapy.METHODS: The number and HER2 status of CTCs out of 30ml peripheral blood were assessed in 642 patients using the CellSearch System (Janssen Diagnostics, USA). The cutoff for CTC positivity was the presence of at least 1 CTC, and the cutoff for HER2 positivity of CTCs was the presence of at least 1 CTC with a strong HER2 staining.RESULTS: 258 (40.2%) of the 642 patients were positive for CTCs (median 2; range 1-1,689). 149 (57.8%) of these 258 patients had at least 1 CTC with strong HER2 staining. The presence of HER2-positive CTCs was not associated with tumor size (p = 0.335), histopathological grading (p = 0.976), hormone receptor status (ER: p = 0.626, PR: p = 0.263) or axillary lymph node involvement (p = 0.430). Overall, 83 (32.2%) of the CTC-positive patients exclusively had CTCs with strong HER2 staining, whereas 31 (12.0%) had only CTCs with negative HER2 staining. Within-sample variation in the HER2 status of CTCs was found in 86 (57.8%) of the 149 patients with more than 1 CTC.CONCLUSION: This study demonstrated that discordance between the HER2 expression of CTCs and that of the primary tumor frequently occurs in early breast cancer. Future follow-up evaluation will assess whether this discrepancy may contribute to trastuzumab resistance.

AB - BACKGROUND: HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the primary tumor and circulating tumor cells (CTCs). This study analyzed the HER2 status of CTCs in patients with HER2-positive primary breast cancer at the time of diagnosis. Aim of the study was to assess potential discordance of HER2 status between primary tumor and CTCs, as this may have important implications for the use of HER2-targeted therapy.METHODS: The number and HER2 status of CTCs out of 30ml peripheral blood were assessed in 642 patients using the CellSearch System (Janssen Diagnostics, USA). The cutoff for CTC positivity was the presence of at least 1 CTC, and the cutoff for HER2 positivity of CTCs was the presence of at least 1 CTC with a strong HER2 staining.RESULTS: 258 (40.2%) of the 642 patients were positive for CTCs (median 2; range 1-1,689). 149 (57.8%) of these 258 patients had at least 1 CTC with strong HER2 staining. The presence of HER2-positive CTCs was not associated with tumor size (p = 0.335), histopathological grading (p = 0.976), hormone receptor status (ER: p = 0.626, PR: p = 0.263) or axillary lymph node involvement (p = 0.430). Overall, 83 (32.2%) of the CTC-positive patients exclusively had CTCs with strong HER2 staining, whereas 31 (12.0%) had only CTCs with negative HER2 staining. Within-sample variation in the HER2 status of CTCs was found in 86 (57.8%) of the 149 patients with more than 1 CTC.CONCLUSION: This study demonstrated that discordance between the HER2 expression of CTCs and that of the primary tumor frequently occurs in early breast cancer. Future follow-up evaluation will assess whether this discrepancy may contribute to trastuzumab resistance.

KW - Adult

KW - Aged

KW - Biomarkers, Tumor

KW - Breast Neoplasms

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Middle Aged

KW - Neoplasm Staging

KW - Neoplastic Cells, Circulating

KW - Receptor, ErbB-2

KW - Translational Medical Research

KW - Trastuzumab

KW - Clinical Trial, Phase III

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1371/journal.pone.0173593

DO - 10.1371/journal.pone.0173593

M3 - SCORING: Journal article

C2 - 28586395

VL - 12

SP - e0173593

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 6

ER -